TapImmune News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

13.09.18	NMRD Turning Heads, EVFM Awaits Contraceptive Gel Data, SLDB Making Solid Gains (RTTNews)
19.06.18	VSTM Turns Heads, PTCT On Fire, CBPO Gets A Suitor, TPIV Up 134% This Month (RTTNews)
14.06.18	GALT Vaults As NASH Research Sparks Interest, MDGL Abuzz, MACK Awaits Data (RTTNews)
12.06.18	Animoto Survey Highlights Video Marketing's Popularity on Social Media Amongst Small Business (PR Newswire)
08.06.18	TapImmune Announces Pricing of $70 Million Private Placement (PR Newswire)
31.05.18	TapImmune to Present at the Jefferies 2018 Global Healthcare Conference (PR Newswire)
31.05.18	OGEN Plays It Safe, MOTS Awaits Data In Q4, EXAS Soars On ACS New Guideline (RTTNews)
30.05.18	TapImmune to Present at 2018 Sachs Associates Immuno-Oncology BD&L and Investment Forum (PR Newswire)
25.05.18	AllianceBernstein National Municipal Income Fund Releases Monthly Portfolio Update (PR Newswire)
23.05.18	TapImmune to Host Investor Webinar on Thursday, May 24th to Discuss Proposed Merger with Marker Therapeutics and Its Transformational T Cell Therapy Platform (PR Newswire)
22.05.18	TapImmune Expands Scientific Advisory Board with Cancer Immunotherapy Pioneers James P. Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., from the MD Anderson Cancer Center (PR Newswire)
16.05.18	TapImmune Creates Scientific Advisory Board to Support Clinical Development of Multi-Antigen Cell Therapy Platform (PR Newswire)
15.05.18	TapImmune to Host Investor Breakfast to Discuss Proposed Merger with Marker Therapeutics (PR Newswire)
15.05.18	TapImmune and Marker Therapeutics Announce Entry into Merger Agreement, Creating a Transformational Immuno-Oncology Platform (PR Newswire)
07.05.18	TapImmune to Present at 2018 NYC Oncology Investor Conference (PR Newswire)
01.05.18	TapImmune to Present at 2018 Disruptive Growth & Healthcare Conference (PR Newswire)
05.04.18	TapImmune Provides Fourth Quarter and Year-End 2017 Corporate and Clinical Update (PR Newswire)
29.03.18	TapImmune to Provide Fourth Quarter and Full Year 2017 Business Update Conference Call and Webcast (PR Newswire)
14.03.18	TapImmune to Present at Two Upcoming Investor Conferences (PR Newswire)
28.02.18	STAAR Surgical Reports Fourth Quarter and Full Year 2017 Results (PR Newswire)
06.02.18	TapImmune to Participate in Two Upcoming Investor Conferences (PR Newswire)
03.01.18	TapImmune to Present at Biotech Showcase™ 2018 (PR Newswire)
12.12.17	TapImmune Announces Enrollment of First Patient in Phase 2 Clinical Trial for Treating Triple-Negative Breast Cancer Funded by U.S. Department of Defense (PR Newswire)
11.12.17	TapImmune, Inc. Presentation Now Available for On-Demand Viewing (PR Newswire)
11.12.17	TapImmune, Inc. Presentation Now Available for On-Demand Viewing (PR Newswire)
06.12.17	TapImmune Appoints Richard Kenney, M.D., F.A.C.P., as Acting Chief Medical Officer (PR Newswire)
04.12.17	Live Investor Conference & Webinar: NASDAQ, NYSE and OTC companies present December 7th (PR Newswire)
04.12.17	TapImmune Inc. to Webcast, Live, at VirtualInvestorConferences.com December 7 (PR Newswire)
04.12.17	Live Investor Conference & Webinar: NASDAQ, NYSE and OTC companies present December 7th (PR Newswire)
04.12.17	TapImmune Inc. to Webcast, Live, at VirtualInvestorConferences.com December 7 (PR Newswire)
21.11.17	TapImmune to Present at 29th Annual Piper Jaffray Healthcare Conference (PR Newswire)
17.11.17	TapImmune to Present at World Vaccine & Immunotherapy Congress West Coast (PR Newswire)
16.11.17	FDA Nod For Breast Cancer Combo Therapy, RARE Scripts History, EDAP Disappoints (RTTNews)
15.11.17	TapImmune Provides Third Quarter 2017 Corporate and Clinical Update (PR Newswire)
14.11.17	TapImmune Completes Patient Enrollment Ahead of Schedule in Phase 2 Cancer Vaccine Study for Treating Triple-Negative Breast Cancer (PR Newswire)
13.11.17	TapImmune to Provide Third Quarter 2017 Business Update Conference Call and Webcast (PR Newswire)
10.11.17	/R E P R I S E -- Avis aux médias: événement en matière d'infrastructure pour Lac-Saguay/ (PR Newswire)
09.11.17	Invitation médias - Symposium 2017 - Changements climatiques et adaptation - Une science de qualité et pertinente pour le Québec (PR Newswire)
18.10.17	A Personal Letter to the Shareholders from TapImmune's New Chief Executive Officer (PR Newswire)
17.10.17	/R E P E A T -- Boralex and Infinergy announce joint venture for 325 MW onshore wind in the UK/ (PR Newswire)
12.10.17	TapImmune to Present at the 2017 BioFlorida Conference (PR Newswire)
25.09.17	TapImmune Appoints Peter Hoang as President and Chief Executive Officer (PR Newswire)
20.09.17	Kaiser Permanente Delivers on Bold Investment Commitments to Deliver Best Care, Convenience and Experience (PR Newswire)
31.08.17	TapImmune Provides Second Quarter 2017 Corporate and Clinical Update (PR Newswire)
29.08.17	TapImmune to Provide Second Quarter 2017 Business Update Conference Call and Webcast (PR Newswire)
08.08.17	TapImmune Amends Phase 2 Clinical Trial to Focus on Larger Population of Women with Platinum-Sensitive Ovarian Cancer with Greatest Unmet Need for New Treatments (PR Newswire)
18.07.17	TapImmune CEO Glynn Wilson to Chair Panel Discussion on the Future of Combination Therapies in Oncology (PR Newswire)
14.06.17	TapImmune to Present at 2017 Biotechnology Innovation Organization International Convention (PR Newswire)
01.06.17	Award-Winning LEGO® BOOST Building and Coding Set Available for Online Preorder Today (PR Newswire)
31.05.17	TapImmune Provides First Quarter 2017 Corporate and Clinical Update (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Swiss Re	133.55	4.50 %	K V
Swiss Life Hldg	693.60	0.93 %	K V
Zurich Insur Gr	552.80	0.91 %	K V
Kuehne+Nagel Int	206.60	0.78 %	K V
Sonova Hldg	294.00	0.58 %	K V
Sika	228.20	-1.04 %	K V
Part Grp Hldg	1’264.50	-1.56 %	K V
Geberit	538.20	-1.61 %	K V
Alcon	75.22	-1.75 %	K V
Lonza Grp	532.80	-2.81 %	K V

Nachrichten zu TapImmune Inc

Aktien Top/Flop

Meistgelesene Nachrichten